Islet transplantation is one of the most promising treatments for an unstable form of type 1 diabetes. However, islet transplantation still has some obstacles, such as low success rate of islet isolation, difficulty to obtain long-term insulin freedom, and adverse events related to transplant protocol. We describe the adverse events of current clinical islet transplantation at our institute in this report. Nine type 1 diabetic patients received 17 islet infusions from March 2005 to October 2008. The islet infusion procedure and immunosuppression regimen were based on a modified Edmonton protocol. Severe adverse events (SAEs) were defined as events that were more than grade 3 according to the Terminology Criteria for Adverse Events in Trials of Adult Pancreatic Islet Transplantation, version 4.1 (Collaborative Islet Transplant Registry, CITR). Sixteen events were reported as SAEs and among them 12 events were probably or definitely related to transplant protocols; all occurred within 1 year after infusion except for one. Five adverse events (31%) occurred within 10 days after transplantation and were related to infusion procedures. Seven events (44%) occurred after 50 days and were related to immunosuppressive therapy. SAEs related to the protocol included three events of elevated liver enzymes, two of hemorrhage into gall bladder or peritoneal cavity, two of neutropenia, two of infection, one of vomiting, one of diarrhea, and one of renal dysfunction. All events were grade 3, except for one case that was grade 4 of neutropenia. All SAEs resolved with no sequelae. Neoplasms and deaths were not observed in our study. The present study suggests need to improve both infusion procedure and immunosuppressive strategy from the view of preventing SAEs.
INTRODUCTION
problems with immunosuppression or other concomitant agents: mouth ulcers, diarrhea, and acne (1, 5, 14) . Longer term risks also are malignant disease and serious infec-Islet transplantation is the one of most promising therapies for unstable type 1 diabetes. Several clinical tion, although these are rare (15) . Therefore, analysis of adverse events is important step on the way to improve-trials of islet transplantation have been performed since results of the Edmonton group were published in 2000 ment in results of islet transplantation. We started clinical trials of islet transplantation based (17) . In recent years, many reports revealed benefits of islet transplantation such as improvement of glycemic on the Edmonton protocol in 2005, and a novel protocol that has graft-protective immunosuppression strategy stabilization, quality of life, and long-term diabetic complications (2, 3, 16, 18, 20, 21) . However, results of islet has been performed since last year (6). We focused on adverse events of islet transplantation in our institute in transplantation need to further improve to justify its disadvantages. Fiorina 
Islet Transplantation
Number of Adverse Events Islet isolations were performed as previously reported All patients had adverse events. SAEs related to (6-9,12). The criteria for the approval of clinical transeither the infusion procedure or immunosuppressive plantation are that islets yield more than 4,000 islet therapy occurred in four patients (45%) in year 1 postequivalents/kg, purity more than 30%, viability more first infusion (Table 1 ). Twelve events (4.4%) among all than 70%, tissue volume less than 10 ml, endotoxin level 270 AEs were SAEs related to transplant protocol. There less than 5 endotoxin units/kg, and a negative Gram stain.
were no SAEs in patients who were transplanted using The islet infusion was performed as a percutaneous the second generation protocol although observation transhepatic procedure performed in Interventional Radiperiods (0.42 person-years) were limited. ology using the Seldinger technique and sonographic guidance. Once access was confirmed by portogram, a Clinical Course of Adverse Events Kumpe catheter was inserted within main portal vein.
Most of AEs and all SAEs occurred within first year Islets were infused by gravity and using the bag techafter transplantation ( Table 2 ). We analyzed SAEs nique (10).
related to either infusion procedure or immunosuppres-For the first seven patients, immunosuppression regision therapy more precisely. All SAEs related to infumen was based on the Edmonton protocol (17) (firstsion procedure occurred and resolved within 4 months generation protocol). The last two patients received after each infusion, and durations of SAEs related to administrations of thymoglobulin (Genzyme Corp., MA, immunosuppression therapy lasted 2 weeks or less (Fig. USA) for induction of immunosuppression, tacrolimus 1). Among 12 SAEs related to the protocol, all events and mycophenolate mofetile for maintenance, and ethresolved without residual effects. There were no events anercept (Wyeth Pharmaceutical Corp., NJ, USA) and resulting in death or chronic disability. anakinra (Biovitrium Corp., Stockholm, Sweden) for SAEs related to the protocol included three events anti-inflammation during islet transplantation (secondof elevated liver enzymes, two of hemorrhage into gall generation protocol). bladder or peritoneal cavity, two of neutropenia, two of When patients received less than the optimal dose of infection, one of vomiting, one of diarrhea, and one of 10,000 islet equivalent/kg body weight or did not achieved renal failure. Other SAEs were ischemic heart disease, insulin independence, islet infusions were repeated up to a diarrhea, and elevated liver enzymes for temporally used total of three.
concomitants; antibiotics. All events were grade 3, except for one case that was grade 4 of neutropenia.
Adverse Events
There was no malignant disease. All adverse events (AEs) were reported according to the Terminology Criteria for Adverse Events in Trials DISCUSSION of Adult Pancreatic Islet Transplantation, version 4.1 (Collaborative Islet Transplant Registry, CITR) which Although islet transplantation is a relatively safe procedure, adverse events and serious adverse events are was based on the Common Terminology Criteria for Adverse Events of the National Cancer Institute, version frequent. More than half of patients experienced SAEs in the present study, and CITR reported similar statis-3.0 and categorized as grade 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), and 5 (death) (1). AEs tics; 34% of patients who received islet transplantation alone had SAEs (1). However, the higher than usual more than grade 3 were defined as severe adverse events (SAEs). The relationship between each adverse events incidence of adverse events is in part related to the fact that there is close follow-up of the patients and centers and transplant protocol was categorized as causality 1 (not related), 2 (unlikely), 3 (possibly), 4 (probably), and abide to the strict rules of reporting imposed by the FDA. The rate of SAEs in our institution was higher 5 (definitely) by islet investigators.
than those of CITR, which might be explained by higher RESULTS frequency of SAEs related to infusion procedure. Although access to the portal vein is carefully performed Seven females and two male patients received 17 islet infusions from March 2005 to October 2008. The aver-by dedicated and experienced interventional radiologists, it is potentially difficult to completely avoid bleed-age age at first islet infusion was 43.9 years (SE: 3.9, range: 26-57), and the mean of body mass index was ing and vascular complications (13). In order to avoid Relationships of the adverse event to the immunosuppression therapy and to the infusion procedure are based on classification of "probable" or "Definite." AEs, adverse events; SAEs, severe adverse events. 
